Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Drug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Fineline Cube Dec 6, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...

Company Deals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion

Fineline Cube Dec 6, 2024

China-based ophthalmic medical device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050), has announced plans...

Company Deals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Fineline Cube Dec 6, 2024

US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...

Company Deals Drug

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

Fineline Cube Dec 6, 2024

US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...

Company Drug

AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer

Fineline Cube Dec 6, 2024

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...

Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Fineline Cube Dec 6, 2024

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its...

Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Fineline Cube Dec 6, 2024

US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance...

Company Drug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

Fineline Cube Dec 6, 2024

US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...

Company Drug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Fineline Cube Dec 6, 2024

China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...

Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Fineline Cube Dec 5, 2024

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the...

Company Deals

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million

Fineline Cube Dec 5, 2024

US-based Novavax, Inc. (NASDAQ: NVAX) has reached an agreement to sell its manufacturing facility located...

Hospital Policy / Regulatory

China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care

Fineline Cube Dec 5, 2024

The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...

Company Drug

Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study

Fineline Cube Dec 5, 2024

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...

Company Drug

Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer

Fineline Cube Dec 5, 2024

Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...

Company Drug

CGeneTech’s Cetagliptin Receives NMPA Approval for Type 2 Diabetes Treatment in China

Fineline Cube Dec 5, 2024

The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech...

Company Drug

Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment

Fineline Cube Dec 5, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...

Company

AstraZeneca Appoints Iskra Reic as EVP, International, Amid Leon Wang’s Investigation in China

Fineline Cube Dec 5, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced the appointment of Iskra...

Company Drug

Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC

Fineline Cube Dec 5, 2024

Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...

Company Drug

Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis

Fineline Cube Dec 5, 2024

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...

Company Deals

GSK plc Expands Pipeline with Rgenta Therapeutics Partnership for RNA-Targeted Splice Modulators

Fineline Cube Dec 5, 2024

GSK plc (NYSE: GSK), a leading global pharmaceutical company, continues to bolster its pipeline through...

Posts pagination

1 … 233 234 235 … 647

Recent updates

  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
  • Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.